JP2015501291A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015501291A5 JP2015501291A5 JP2014532118A JP2014532118A JP2015501291A5 JP 2015501291 A5 JP2015501291 A5 JP 2015501291A5 JP 2014532118 A JP2014532118 A JP 2014532118A JP 2014532118 A JP2014532118 A JP 2014532118A JP 2015501291 A5 JP2015501291 A5 JP 2015501291A5
- Authority
- JP
- Japan
- Prior art keywords
- region
- antibody
- fusion protein
- protein according
- regions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161539416P | 2011-09-26 | 2011-09-26 | |
| US61/539,416 | 2011-09-26 | ||
| PCT/US2012/057393 WO2013049254A1 (en) | 2011-09-26 | 2012-09-26 | Hybrid constant regions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015501291A JP2015501291A (ja) | 2015-01-15 |
| JP2015501291A5 true JP2015501291A5 (enExample) | 2015-11-19 |
| JP6205363B2 JP6205363B2 (ja) | 2017-09-27 |
Family
ID=47996377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014532118A Active JP6205363B2 (ja) | 2011-09-26 | 2012-09-26 | ハイブリッド定常領域 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US8952134B2 (enExample) |
| EP (1) | EP2760891B1 (enExample) |
| JP (1) | JP6205363B2 (enExample) |
| CN (1) | CN103974977A (enExample) |
| CA (1) | CA2849765C (enExample) |
| WO (1) | WO2013049254A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9382319B2 (en) | 2011-09-26 | 2016-07-05 | Jn Biosciences Llc | Hybrid constant regions |
| EP2760891B1 (en) | 2011-09-26 | 2018-11-07 | JN Biosciences LLC | Hybrid constant regions |
| EP3553089A1 (en) | 2012-05-10 | 2019-10-16 | Bioatla, LLC | Multi-specific monoclonal antibodies |
| CA2879814A1 (en) * | 2012-08-02 | 2014-02-06 | Jn Biosciences Llc | Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece |
| US20150038682A1 (en) * | 2013-08-02 | 2015-02-05 | Jn Biosciences Llc | Antibodies or fusion proteins multimerized via homomultimerizing peptide |
| CN105722855B (zh) * | 2013-09-05 | 2021-04-23 | Igm生物科学股份有限公司 | 恒定链经修饰的双特异性五价和六价Ig-M抗体 |
| CN106068274A (zh) | 2014-03-05 | 2016-11-02 | Ucb生物制药私人有限公司 | 多聚体Fc蛋白 |
| CN106132994A (zh) * | 2014-03-05 | 2016-11-16 | Ucb生物制药私人有限公司 | 多聚体Fc蛋白 |
| WO2015167948A1 (en) | 2014-04-30 | 2015-11-05 | Albert Einstein College Of Medicine Of Yeshiva University | Tmigd2 and its derivatives as blockers or binders of cancer-expressed hhla2 for immunotherapies |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| PT3247728T (pt) * | 2015-01-20 | 2020-07-16 | Igm Biosciences Inc | Moléculas de ligação do recetor da superfamília do fator de necrose tumoral (fnt) e utilização das mesmas |
| WO2016154593A1 (en) | 2015-03-25 | 2016-09-29 | Igm Biosciences, Inc. | Multi-valent hepatitis b virus antigen binding molecules and uses thereof |
| MX2017012805A (es) * | 2015-04-07 | 2018-04-11 | Genentech Inc | Complejo de unión a antígenos con actividad agonista y métodos de uso. |
| AU2016249404B2 (en) | 2015-04-17 | 2021-01-21 | Igm Biosciences, Inc. | Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof |
| GB201515745D0 (en) * | 2015-09-04 | 2015-10-21 | Ucb Biopharma Sprl | Proteins |
| RU2018130525A (ru) * | 2016-01-27 | 2020-02-27 | Цсл Беринг Ленгнау Аг | РЕКОМБИНАНТНЫЕ Fc-МУЛЬТИМЕРЫ IgG |
| CA3030659A1 (en) * | 2016-07-20 | 2018-01-25 | Igm Biosciences, Inc. | Multimeric gitr binding molecules and uses thereof |
| CA3055790A1 (en) * | 2017-04-07 | 2018-10-11 | Igm Biosciences, Inc. | Modified human igm constant regions for modulation of complement-dependent cytolysis effector function |
| CN110913895B (zh) * | 2017-05-08 | 2024-04-02 | 阿迪马布有限责任公司 | 抗cd3结合结构域和包含它们的抗体以及它们的产生及使用方法 |
| EP3759229A4 (en) * | 2018-02-26 | 2021-12-29 | IGM Biosciences Inc. | Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer |
| CN112513081A (zh) | 2018-06-14 | 2021-03-16 | 生物蛋白有限公司 | 多重特异性抗体构建体 |
| CN112368021B (zh) | 2018-06-14 | 2025-02-21 | 2赛文缇生物公司 | Cd79a嵌合抗原受体 |
| AU2019368289A1 (en) * | 2018-10-23 | 2021-04-29 | Igm Biosciences, Inc. | Multivalent IgM- and IgA-Fc-based binding molecules |
| EP3880248A4 (en) * | 2018-11-14 | 2022-08-10 | JN Biosciences, LLC | MULTIMERIC HYBRID FC PROTEINS FOR IV IG REPLACEMENT |
| KR20220035369A (ko) | 2019-06-07 | 2022-03-22 | 아디맵 엘엘씨 | 고 친화도 항-cd3 항체, 및 이의 생성 및 사용 방법 |
| MX2021015495A (es) * | 2019-06-14 | 2022-04-18 | 2Seventy Bio Inc | Composiciones y métodos para tratar cáncer. |
| JP7554837B2 (ja) * | 2020-02-27 | 2024-09-20 | 華輝安健(北京)生物科技有限公司 | 可溶性ａｃｅ２及び融合タンパク質、並びにその適用 |
| KR102450007B1 (ko) * | 2020-10-16 | 2022-10-04 | 주식회사 아이엠바이오로직스 | IgM 영역을 이용한 융합단백질 플랫폼 |
| MX2023015461A (es) * | 2021-06-17 | 2024-01-18 | Fapon Biotech Inc | Inmunoglobulina quimerica. |
| EP4370541A1 (en) | 2021-07-14 | 2024-05-22 | 2seventy bio, Inc. | Engineered t cell receptors fused to binding domains from antibodies |
| AU2023248532A1 (en) | 2022-04-08 | 2024-11-21 | Regeneron Pharmaceuticals, Inc. | Multipartite receptor and signaling complexes |
| CN118369336A (zh) * | 2022-04-15 | 2024-07-19 | Im生技股份有限公司 | 具有改进半衰期的融合蛋白平台 |
| WO2024196707A2 (en) * | 2023-03-17 | 2024-09-26 | The Board Of Trustees Of The University Of Illinois | Chimeric antibody molecules based on tetrameric teleost immunoglobulin m |
| CN118339300A (zh) * | 2024-01-02 | 2024-07-12 | 江苏集萃药康生物科技股份有限公司 | 产生人源化抗体的动物模型及其构建方法 |
| KR20250173023A (ko) * | 2024-05-30 | 2025-12-10 | 주식회사 아이엠바이오로직스 | J 사슬에 연결되는 링커 및 이를 포함하는 j 사슬 복합체 |
| CN119638846B (zh) * | 2025-01-09 | 2025-11-04 | 康复大学青岛中心医院 | uMtCK抗体或其抗原结合片段 |
| CN121405821B (zh) * | 2025-12-30 | 2026-04-10 | 山东大学 | 一种融合蛋白及在制备治疗或预防乙肝病毒产品中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8719963D0 (en) * | 1987-08-24 | 1987-09-30 | Cattaneo A | Recombinant dna products |
| DE10001372A1 (de) | 2000-01-14 | 2001-08-02 | Deutsches Krebsforsch | Anti-CD3-Einzelketten-Antikörper mit humanem Cmu3- und Cmu4- Domänen |
| US7951378B2 (en) * | 2000-04-28 | 2011-05-31 | Planet Biotechnology Inc. | Immunoadhesin comprising a chimeric ICAM-1 molecule produced in a plant |
| US7754208B2 (en) * | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| EP1361892A4 (en) * | 2001-01-17 | 2004-10-13 | Trubion Pharmaceuticals Inc | BINDING DOMAIN FUSION PROTEIN Immunoglobulin |
| DK1366067T3 (da) * | 2001-03-07 | 2012-10-22 | Merck Patent Gmbh | Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed |
| EP1687486A1 (en) * | 2003-11-13 | 2006-08-09 | DSM IP Assets B.V. | Use of a vulcanised thermoplastic elastomer or styrene-ethylene-butadiene-styrene polymer as infill material in artificial turf systems |
| WO2008148884A1 (en) * | 2007-06-08 | 2008-12-11 | Universite De La Mediterranee | Compositions and methods for treating pancreatic tumors |
| EP2760891B1 (en) | 2011-09-26 | 2018-11-07 | JN Biosciences LLC | Hybrid constant regions |
-
2012
- 2012-09-26 EP EP12836751.3A patent/EP2760891B1/en active Active
- 2012-09-26 CN CN201280047037.9A patent/CN103974977A/zh active Pending
- 2012-09-26 CA CA2849765A patent/CA2849765C/en active Active
- 2012-09-26 WO PCT/US2012/057393 patent/WO2013049254A1/en not_active Ceased
- 2012-09-26 US US13/627,929 patent/US8952134B2/en active Active
- 2012-09-26 JP JP2014532118A patent/JP6205363B2/ja active Active
-
2014
- 2014-11-17 US US14/543,845 patent/US20150073130A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015524821A5 (enExample) | ||
| JP7790754B2 (ja) | Ｃｄ３を標的とする抗体、二重特異性抗体及びその使用 | |
| JP7862028B2 (ja) | 免疫細胞活性化のための二重特異性抗体 | |
| SI2699264T1 (en) | Antibodies and other molecules that bind b7-h1 and pd-1 | |
| CA2929256C (en) | Production of t cell retargeting hetero-dimeric immunoglobulins | |
| HRP20210739T1 (hr) | Molekule koje vežu antigen i sadrže trimer obitelji tnf liganada | |
| JP2023528036A (ja) | Ｔｉｇｉｔに対する抗体 | |
| JP2020508655A5 (enExample) | ||
| EP4464333A3 (en) | Anti-death receptor antibodies and methods of use thereof | |
| HRP20192346T1 (hr) | Molekule anti-lag-3 antitijela i njihove uporabe | |
| RU2018142544A (ru) | Биспецифические связывающие белки и пути их применения | |
| EA202092460A1 (ru) | Антитела к ox40 и способы применения | |
| HRP20240415T1 (hr) | Kimerni antigenski receptori antigena kapa mijeloma i njihova upotreba | |
| JP2019513817A (ja) | Ｔｉｇｉｔに対する抗体 | |
| JP2019536470A5 (enExample) | ||
| CN109862910A (zh) | 破坏巨噬细胞上的Fc受体接合增强抗SIRPα抗体疗法的功效 | |
| JP2021516952A (ja) | 新規な抗体分子、その調製方法及びその使用 | |
| JP2019524693A5 (enExample) | ||
| BR112019024419A2 (pt) | anticorpos compreendendo regiões constantes pesadas modificadas | |
| JP2018525999A5 (enExample) | ||
| HRP20180937T1 (hr) | Poboljšavanje transporta terapijskih molekula kroz krvno-moždanu barijeru | |
| JP2019513725A5 (enExample) | ||
| KR20180095086A (ko) | 인간화된, 마우스 또는 키메라 항-cd47 단클론 항체 | |
| JP2016507523A5 (enExample) | ||
| CA2896548A1 (en) | Multivalent binding protein compositions |